Sun Pharmaceutical Industries Ltd. has announced the acquisition of Nasdaq-listed Checkpoint Therapeutics ... UNLOXCYT (cosibelimab-ipdl), to its pipeline. The deal, expected to close in the ...

D. Boral Capital reaffirmed their buy rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) in a research ...

Checkpoint Therapeutics is a clinical-stage ... Checkpoint’s broad pipeline consists of fully-human, immuno-oncology and checkpoint inhibitor antibodies licensed from the Dana-Farber Cancer ...

In March 2025, Checkpoint announced that it entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sun Pharmaceutical Industries, Inc. (“Sun Pharma”), and a wholly ...

Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; ...

Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) is expected to announce its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq ... in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results ...

(MENAFN- GlobeNewsWire - Nasdaq) UNLOXCYTTM (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., March 28 ...

CHECKPOINT THERAPEUTICS, INC. CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share amounts) (Unaudited) For the year ended December 31, 2024 2023 Revenue - related party ...